MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rpth.2025.103280

Медицинская библиотека · Research and practice in thrombosis and haemostasis · 2025

Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study.

Olasupo Omotola O, Iserman Emma, Keepanasseril Arun, Ibrahim Quazi, Ali Al-Housni Zainab Salim, Germini Federico, Tarride Jean-Eric, Mbuagbaw Lawrence, Jackson Shannon, Blydt-Hansen Ingrid, Bech Michelle, Woo Celina, Belletrutti Mark, Iorio Alfonso, Matino Davide, Association of Hemophilia Clinic Directors of Canada (AHCDC)

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Comparative safety data on hemophilia therapies are scarce.

OBJECTIVES

To compare the risk of adverse drug reactions (ADRs) associated with extended-half-life (EHL) and standard-half-life (SHL) clotting factor therapies, bypassing agents, and emicizumab.

METHODS AND ANALYSIS: We analyzed Canadian Bleeding Disorders Registry data from 2018 to 2022. ADRs were defined as adverse events (AEs) if definitely, possibly, or probably treatment-related. We compared incidence rates of ADRs between therapies to estimate incidence rate ratios and 95% CIs.

RESULTS

We found a total of 183 AEs and 67 ADRs. Reported AEs varied from 6.1 to 14.8 events per 1000 patients per year. Allergic reactions were the most prevalent ADRs. A higher incidence of allergic reactions was associated with emicizumab compared with EHL (IRR 3.59; 95% CI, 1.43-9.00) and SHL (IRR 11.86; 95% CI, 4.73-29.72) clotting factor concentrates. Events reflecting inadequate hemostatic control and other unintended events occurred more often with emicizumab compared with SHL (IRR 6.39, 95% CI, 1.29-31.63) and EHL concentrates (IRR 2.77, 95% CI, 0.56-13.72). No inhibitor development was reported with emicizumab or bypassing agents. Cases of neurological events and thrombosis were reported when emicizumab was used in combination with other hemostatic therapies.

CONCLUSION

This study highlights the relative safety of therapies approved for the management of hemophilia A and B. While more ADRs were reported with emicizumab, no inhibitor development was observed. However, novelty bias cannot be ruled out. Our estimates are limited by the use of routinely collected data with no adjustment for confounding due to low event rates and missing data.

Для цитирования: Olasupo Omotola O, Iserman Emma, Keepanasseril Arun, Ibrahim Quazi, Ali Al-Housni Zainab Salim, Germini Federico, Tarride Jean-Eric, Mbuagbaw Lawrence, Jackson Shannon, Blydt-Hansen Ingrid, Bech Michelle, Woo Celina, Belletrutti Mark, Iorio Alfonso, Matino Davide, Association of Hemophilia Clinic Directors of Canada (AHCDC). Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study.. Research and practice in thrombosis and haemostasis. 2025. DOI: 10.1016/j.rpth.2025.103280.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.